EGFR and cancer: Other authors found that EGFR-TKI affects the cancer related networks of pro-inflammatory cytokines and activates the lymphocytic responses; this evidence suggests a possible synergism between the EGFR molecular pathway inhibition and immune system modulation in promoting tumor shrinkage [23,24].